Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Arise AB (publ) has established a Green Financing Framework and investigates the possibility to issue green senior unsecured bonds

Arise AB (publ) (“Arise” or “the Company”), today announces its new Green Financing Framework (the “framework”). The framework outlines details for investments exclusively in renewable energy. Through these investments, Arise wishes to promote low carbon solutions and climate-resilient development. Please see the Green Financing Framework available on Arise’s website for further details, www.arise.se.   To confirm the framework’s alignment with the 2021 version of the ICMA Green Bond Principles, Arise has obtained a second-party opinion from Cicero Shades of Green. Cicero Shades of

Clinical study published regarding XNK Therapeutics’ NK cell-based product

XNK Therapeutics AB (“XNK”) today announced that the first-in-human Phase I study ACP-001, performed at the Karolinska University Hospital in Huddinge, Sweden, has been published in Cell Reports Medicine. The study demonstrates that XNK’s autologous natural killer (NK) cell-based immunotherapy is feasible. Furthermore, it shows a good safety profile and promising efficacy data as consolidation treatment following autologous stem cell transplantation in patients newly diagnosed with multiple myeloma.“XNK is focused on the clinical development of autologous natural killer cell-based products

Citycon Board’s asset distribution proposal to the Annual General Meeting

CITYCON OYJ   Stock Exchange Release   17 February 2022 at 09:05 hrsThe Board of Directors of Citycon Oyj has decided to propose to the Annual General Meeting to be held on 22 March 2022 asset distribution as follows.The Board of Directors proposes that based on the balance sheet to be adopted for the financial period ended on 31 December 2021, no dividend is distributed by a resolution of the Annual General Meeting.Nonetheless, the Board of Directors proposes that the Board of Directors be authorized to decide in its discretion on the distribution of assets from the invested

Interim Q4 and Year-End 2021 Report

Continued Sportsook Growth in Q4; All Time High in Revenues in Year 2021Key Facts for the 4[th] Quarter 2021 (1[st] October 2021 – 31[th] December 2021) Continued growth in the Sportsbook All figures are compared to the same quarter last year if not explicitly stated otherwise · Revenues decreased by 19.03 % to €9,618,463 (€11,879,282). · EBIT decreased by 64.07% to €1,452,790 (€4,043,740). · EBIT margin of 15.10% (34.04%). · Customer deposits decreased by 18.90% to €20,507,189 (€25,286,513). · 64,604 new registered customers (71,767), decrease of 9.98%. · 15,551

Acroud publishes Year-End Report 2021: AN EVENTFUL QUARTER WITH FOCUS ON OPERATIONAL EFFICIENCY

Fourth Quarter 2021 •         Revenue amounted to EUR 6 540 (2 497) thousand, corresponding to a growth of 162% (-24%) and an organic growth of -11.1% (-23.7%). •         EBITDA amounted to EUR 817 (1 292) thousand. Adjusted EBITDA (before items affecting comparability related to restructuring) was EUR 1 062 (1 023) thousand. •         Profit after tax was EUR -356 (-685) thousand. Adjusted profit after tax (before items affecting comparability and currency effects) was EUR -264 (94) thousand. •         Earnings per share after dilution amounted to EUR -0.003 (-0.008). Adjusted

Aker Carbon Capture and Northern Lights JV to collaborate on accelerating the carbon capture and storage market through full value-chain offerings

Aker Carbon Capture and Northern Lights JV have signed a non-exclusive Memorandum of Understanding (MoU) to collaborate on realization of Carbon Capture and Storage (CCS) projects in Norway and across Europe. Together, the two companies represent a full value chain offering from carbon capture through transport and storage. The MoU also seeks to optimize logistics and standardize ship-shore interfaces.Valborg Lundegaard, Chief Executive Officer of Aker Carbon Capture said: “Through the Longship project, Norway has taken a leadership position in enabling industrial decarbonization through

AQ Group AB (publ): Year-end report 2021

Fourth quarter, October-December 2021 in brief · Record sales despite continued shortage of components and labor · Net sales increased by 19.2% to SEK 1,498 million (1,256)  · Operating profit (EBIT) decreased by 9.4% to SEK 113 million (125)  · Profit after financial items (EBT) decreased by 0.5% to SEK 110 million (111)  · Profit margin before tax (EBT %) was 7.4% (8.8)  · Cash flow from operating activities decreased by 164.4% to SEK -105 million (163) · Earnings per share after tax decreased by 5.4% to SEK 4.76 (5.03) Full year 2021 in brief · Highest

Careium reports year-end report 2021

The quarter in summary · Careium’s net sales amounted to SEK 162.3 million (144.7), an increase of 12.2 percent. Service sales amounted to 126.8 million (109.7) an increase of 15.6 percent. Product sales amounted to 35.5 million (35.0) an increase of 1.4 percent. · Gross margin increased to 40.5 percent (39,6). · EBITDA amounted to SEK 16.9 million (19.8), a decrease of 17.2 percent. · Operating profit (EBIT) amounted to SEK 0.9 million (6.3) excluding restructuring costs of SEK 1.4 million corresponding to an operating margin of 0.6 percent (4.4). Including restructuring

Bioretec Ltd’s Financial Statements Bulletin 2021 (unaudited): Major steps in preparing for commercialization of RemeOs™

Bioretec Ltd    Company announcement     17 February 2022 at 9.00 a.m. EETThis is a summary of Bioretec Ltd’s Financial Statements Bulletin 2021. The complete Financial Statements Bulletin with tables is attached to this release and available at www.bioretec.com /investors-in-english/reports-and-presentations. JULY–DECEMBER 2021 IN BRIEF · Net sales increased by 24.2% and amounted to EUR 956 thousand (7-12/2020: EUR 770 thousand). · Sales margin was EUR 598 (554) thousand and 62.6% (71.9%) of net sales, up by 8.1%. · Net profit (loss) amounted to EUR -3,226 (-892) thousand.

BONESUPPORT Holding AB (publ) – Publishes full year report 2021

Lund, Sweden, 08:00 CET, February 17, 2022 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the fourth quarter 2021 and the full year 2021. STRONG SALES GROWTH, DESPITE OMICRON BREAK-OUT OCTOBER – DECEMBER 2021 · Net sales increased by 15 percent (21 percent at constant exchange rates) and amounted to SEK 61.4 million (53.2). · The North America (NA) segment reported a sales increase of 22 percent (30 percent at constant exchange rate). · The Europe & Rest of the World (EUROW)

Year-end report 1 January–31 December 2021

Fourth QUARTER (1 October–31 December 2021) · Net sales for the quarter amounted to MSEK 79 (26). · Operating profit/loss before depreciation and amortisation (EBITDA) before items affecting comparability totalled MSEK 46 (1) and after items affecting comparability MSEK 32 (1). · Operating profit/loss (EBIT) before items affecting comparability amounted to MSEK 31 (-15) and after items affecting comparability to MSEK 17 (-15). · Profit/loss before tax before items affecting comparability was MSEK 28 (-23) and after items affecting comparability MSEK 13 (-41). · Profit/loss

Interim Report Fourth Quarter 2021

Record High Revenues of €213 Million in 2021FOURTH QUARTER* · Revenues increased by 14.7% to €50.9 million (44.4). · Revenues Pro-Forma basis increased by 24.0% to €42.6 million (34.4). · EBITDA decreased by 9.1 % to €7.5 million (8.3). · EBITDA Pro-Forma basis increased by 24.0% to €7.7 million (6.2). · The EBITDA margin amounted to 14.8% (18.6%). · EBITDA margin Pro-Forma basis amounted to 18.1% (18.1%) · EBIT decreased by 18.7% to €5.1 million (6.3). · EBIT Pro-Forma basis increased by 25.1% to €5.3 million (4.3). · Earnings after tax (before €59.7 million

Citycon 2021: Strong operating figures combined with positive fair value development

Citycon Oyj   Stock exchange release 17 February 2022 at 09:00 hrs- Strong quarter in like-for-like tenant sales (+7.6%) and footfall (+8.2%). Like-for-like tenant sales increased +3.8% in 2021 compared to 2020, which was partially pre-pandemic. Compared to 2019, like-for-like tenant sales and footfall were +0.5% and -14.4%, respectively.- Rent collection was 96% for the full year, continuing to exhibit one of the best collection rates in the industry- The operating properties recorded a fourth consecutive quarter of uplift in valuations. In total fair value gain in 2021 was EUR 48.6

Q4 and full year report January – December 2021

Significant investment activity in new and existing marketsHighlights fourth quarter 2021 · Agreement for acquisition in Switzerland to acquire 100% of the share capital of Swiss Bankers Prepaid Services AG, a market-leading Swiss payments company pending regulatory approval, in line with DDM’s growth strategy · Entered into a strategic partnership in Italy with Borgosesia S.p.A. to invest in Italian mid-market real estate-backed special situation opportunities of up to EUR 100m over the next three years and executed first co-investment in December · Investment in Poland in a

Q4 and full year report January – December 2021

Significant investment activity in new and existing marketsHighlights fourth quarter 2021 · Agreement for acquisition in Switzerland to acquire 100% of the share capital of Swiss Bankers Prepaid Services AG, a market-leading Swiss payments company pending regulatory approval, in line with DDM’s growth strategy · Entered into a strategic partnership in Italy with Borgosesia S.p.A. to invest in Italian mid-market real estate-backed special situation opportunities of up to EUR 100m over the next three years and executed first co-investment in December · Investment in Poland in a

The EU Commission has approved the remaining 50 million euros of the hybrid loan by the State of Finland to Finnair

Finnair Plc                  Stock Exchange Release                 17 February 2022 at 9.00 a.m. EET  Finnair announced on 17 March 2021 that the company and the State of Finland had signed an agreement on a hybrid loan of maximum 400 million euros to support Finnair. The decision was made by the Plenary Session of the Government on 18 February 2021. The arrangement has the approval of the EU Commission’s competition authority in line with the European Union’s state aid rules. The company also stated that of the credit limit, approximately 350 million euros can be used by Finnair

Finnair Financial Statements Release 1 January–31 December 2021

Finnair Plc        Financial Statement Release      17 February 2022 at 9.00 a.m. EET Travel increased and EBITDA turned positive; Omicron’s negative impact notable but short-term. October – December 2021 · Earnings per share were -0.06 euros (-0.01)*. · Revenue increased by 305.5% to 413.5 million euros (102.0). · Comparable operating result was -65.2 million euros (-162.9). Operating result was -60.2 million euros (-14.6). · Cash funds were 1,265.7 million euros (823.7) and equity ratio was 11.8 per cent (24.6). · Net cash flow from operating activities was 124.6

ContextVision shows strong momentum in Q4, leading to record sales for the year

STOCKHOLM – Feb 16, 2022- ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today reports its fourth quarter and full year 2021 results. Total sales 2021 reached 98.1 MSEK (94.7), which is the highest revenue in the history of the company. After a slow start to the year, each quarter’s sales have steadily increased, ending with a very strong Q4’s 27.4 MSEK (23.5). Total EBITDA ended at 2.2 MSEK and operating results reached -9.0 MSEK. Medical Imaging The year closed off with record

Eltel Group: Full-year January–December report 2021

October–December 2021 · Net sales EUR 226.3 million (229.2). Total growth -1.2% and organic growth1) in segments -3.1% · Operative EBITA2) EUR 7.0 million (4.0) and operative EBITA margin 3.1% (1.7) · Operative EBITA2) in segments EUR 7.3 million (6.0) and operative EBITA margin in segments 3.6% (2.9) · Items affecting comparability EUR 0.0 million (-5.7) · Operating result (EBIT) EUR 6.9 million (-1.9) and EBIT margin 3.1% (-0.8) · Net result EUR 4.1 million (-7.0) · Earnings per share EUR 0.02 (-0.05), basic and diluted · Cash flow from operating activities EUR

Navamedic ASA: Q4 2021 financial results

Oslo, 17 February 2022 - Navamedic ASA (OSE: NAVA) grew revenues by 63% in the fourth quarter of 2021 compared to the same quarter last year. The company reported revenues of NOK 90.2 million in the fourth quarter of 2021 with an EBITDA of NOK 7.6 million, driven by underlying growth in the portfolio and Mysimba® in particular. The company reiterates its mid-term ambition of building a NOK 500 million company through organic growth.“The fourth quarter of 2021 was strong for Navamedic, resulting in a full year growth of 33%, compared to our targeted growth rate of 20%. We have seen an

IMMray™ PanCan-d – peer-reviewed, blinded validation study now published in Clinical and Translational Gastroenterology

Peer-reviewed validation of study results demonstrating the IMMray™ PanCan-d blood test can detect PDAC with high specificity (99%) and sensitivity (92%), and a test specificity of 99% and sensitivity of 89% for PDAC stages I & II.LUND, SWEDEN – Immunovia AB (publ) announces that the peer-reviewed, blinded study to independently validate the clinical performance of IMMray™ PanCan-d has been published in Clinical and Translational Gastroenterology. The article is available online on the journal’s website. This publication expands on the findings announced on March 29, 2021, and they have now

Dignitana AB Publishes Q4 2021 Interim Report

Continued US growth fuels 25 percent revenue increase Financial highlights Q4 2021 · Net sales amounted to 16.2 MSEK (12.9), an increase of 25 percent over the same period 2020. · Operating result amounted to -11.4 MSEK (-19.7). · Net result after financial items amounted to -11.8 MSEK (-20.8). · Earnings per share were -0,18 SEK (-0,37). · Cash Balance amounted to 14.5 MSEK (78.8). · Average Daily Treatment Revenue (ADTR)* was 155 TSEK (130), an increase of 19 percent over the same period in 2020. Financial highlights January – December 2021 · Net sales

Citycon’s Financial Statements, Corporate Governance Statement and Remuneration Report for 2021 published

CITYCON OYJ   Stock Exchange Release   17 February 2022 at 09:00 hrsCitycon Oyj’s Financial Review for 2021 has been published today. The Financial Review includes the Report by the Board of Directors, Consolidated Financial Statements, Parent Company Financial Statements and Auditor’s Report for the accounting period 1 January – 31 December 2021.The Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements. The format is Extensible Hypertext Markup Language (XHTML), and the primary statements have been labelled with XBRL

There are no items matching the current filter
There are no more items matching the current filter
Back to top